Administration of Systemic Corticosteroids and the Recovery of Gustatory Functions in Patients With COVID-19

NCT05148832 | Completed

• 1 other identifier: Taste COVID-19
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

Coronavirus is a global pandemic with a high mortality rate; it is started in china in 2019 and rapidly spread worldwide, reaching its epidemic peak in March 2020 Coronavirus is a family of viruses that usually affect animals. They also can affect the respiratory system of humans, causing different manifestations such as difficulty in breathing, coughing, fever, invasive lung lesions, and viral pneumonia

Conditions

COVID-19; Olfactory Dysfunction

Keywords

COVID-19; olfactory dysfunction; Gustatory dysfunction; Corticosteriods

Outcome Measures

Primary Outcomes (1)

• Taste sensation

  recovery of taste sensation by questionnaire

  3 months

Study Arms (1)

Cortocosteroid

EXPERIMENTAL

ageusia and anosmia were recruited (that their covid infection was confirmed by using PCR). 10 mg of systemic corticosteroids were prescribed weekly to patients to observe taste and smell sensation recovery. All data were recorded and then analyzed.

Drug: Administration of Systemic Corticosteroid

Interventions

Administration of Systemic Corticosteroid DRUG

10 mg of systemic corticosteroids were prescribed weekly to patients to observe taste and smell sensation recovery.

Cortocosteroid

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• all signs and symptoms were recorded included fever \>38 °C, fatigue, myalgia, arthralgia, sore throat, headache, and its localization (diffuse, frontal, other localization), rhinorrhea, nasal obstruction, epistaxis, tinnitus, and hearing loss, sneezing, cough, sputum production, hemoptysis, dyspnea, respiratory rate \>22, crackling sounds during auscultation, nausea, vomiting, diarrhea, and abdominal pain.

You may not qualify if:

• patients with absolute contraindications for systemic corticosteroids administration, pregnant women, smokers, and patients with any systemic disease or taking any medications that cause loss of taste or smell were excluded from this study.

Sponsors & Collaborators

• Fayoum University: lead

Study Sites (1)

Faculty of Dentistry

Cairo, 21523, Egypt

Location

Related Publications (2)

• Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021 Mar;19(3):141-154. doi: 10.1038/s41579-020-00459-7. Epub 2020 Oct 6.

  PMID: 33024307 BACKGROUND

• Vaira LA, Deiana G, Fois AG, Pirina P, Madeddu G, De Vito A, Babudieri S, Petrocelli M, Serra A, Bussu F, Ligas E, Salzano G, De Riu G. Objective evaluation of anosmia and ageusia in COVID-19 patients: Single-center experience on 72 cases. Head Neck. 2020 Jun;42(6):1252-1258. doi: 10.1002/hed.26204. Epub 2020 Apr 29.

  PMID: 32342566 BACKGROUND

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: associate professor in oral & maxillofacial Surgery Department

Model Details: 67 Covid-19 patients with symptoms of ageusia and anosmia were recruited (that their covid infection was confirmed by using PCR).

Study Record Dates

• First Submitted: December 5, 2021
• First Posted: December 8, 2021
• Study Start: May 1, 2021
• Primary Completion: August 20, 2021
• Study Completion: November 15, 2021
• Last Updated: December 22, 2021

Record last verified: 2021-12

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)